Skip to main content

approvalsWatch: Oncology 110316

US FDA Approvals

The tyrosine kinase inhibitor crizotinib is now indicated for the treatment of metastatic non-small-cell lung cancer (NSCLC) patients harbouring ROS1 rearrangements. Previously crizotinib received US FDA approval for the treatment of late-stage NSCLC patients with ALK alterations.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits